✅ Switching to 2nd line after #IO should be considered in toxicity or disease progression

Do you know which 2nd line treatment options are approved in advanced #HCC ?

Watch the experts knowledge share by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇
ow.ly/7wYi50R46a5

#MedEd

🚨 Have you watched the ILCA webinar on portal hypertension issues in HCC?

With contributions from Coskun Ozer Demirtas, Allaire Manon & Omar Elshaarawy, the webinar is free for ILCA members.

Watch on demand👇
ow.ly/l6o250R4hzk

#MedEd #HCC #LiverTwitter

📢 Digestive Cancers Europe have created a survey on HCC prevention and diagnosis!

The primary targets are clinicians, public health experts and patient advocates.

🗓️ Deadline: 3rd June, 5pm CET

Access the survey👇
ow.ly/6QXm50R3ZV0

#MedEd #HCC #LiverTwitter

❗Subgroup analyses for #HCC patients on #IO & IO combinations show variable hazard ratios across etiologies & liver function

Do you know what scoring systems can assess liver function?

Find out in the micro learning by Ruth He, MD, PhD & Prof. Galle 👇
ow.ly/uF9H50R30yi

#MedEd

💡 A 2024 review of ICI-TKI combinations in advanced solid cancers such as #HCC

The reports suggests camrelizumab-rivoceranib as another first line treatment in unresectable HCC patients next to atezolizumab-bevacizumab

Access here👇
ow.ly/TRKJ50R1XVY

#MedEd #IO

🚨 Applications are open for the AASLD Foundation Emerging Liver Scholars Program!

The program is aimed at medical residents wishing to explore hepatology as a career.

🗓️ Deadline: April 15, 2024

FInd out more information👇
ow.ly/pCqO50R0jTH

#MedEd #HCC #LiverTwitter

✅ TKIs, such as lenvatinib and sorafenib, are recommended treatments for HCC patients who are not eligible for IO first line.

Do know what patient groups this includes?

Find out in the experts knowledge share👇
ow.ly/bb3R50R0RJV

Endorsed by Digestive Cancers Europe

#MedEd #HCC #IO

🎓 Registration is now open for the ILCA School of Liver Cancer!

🗓️ 6 April, 2024
📍 Seoul National University College of Medicine

An immersive learning experience covering the latest #livercancer advancements

Find out more👇
ow.ly/ufWy50R0j05

#MedEd #HCC

🚨 Have you registered for the Global Liver Institute webinar on liver cancer care?

The episode focuses on hepatic encephalopathy, ascites & portal hypertension and the risk factors that contribute to these conditions.

Register below👇
ow.ly/A1e650QZ23q

#MedEd #HCC #LiverCancer

❗ #HCC patients with autoimmune disease or who are post-liver transplant may not be eligible for #IO 1st line

Do you know the recommended treatments for these groups?

Watch the experts knowledge share by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇
ow.ly/8AiC50QYHux

#MedEd

💡 A 2023 paper by F. Jost-Brinkmann et al. on the efficacy of atezolizumab plus bevacizumab in unresectable #HCC

The cohort analysis showed significantly better overall survival and progression free survival compared to TKIs

Access here👇
ow.ly/H6BI50QYCiU

#MedEd #IO

Have you read the Global Liver Institute article on #livercancer ?

Including:
✅Stanford study suggests new screening guidelines for diabetes and liver cancer
✅Canadian/French research team identifies biomarker related to treatment failure

Read here👇
ow.ly/pLyN50QQFB3

#MedEd #HCC

✅ IO and IO combinations, are effective treatments for patients with advanced HCC

Do you know how to treat their inflammatory side effects, known as irAEs?

Find out in the micro learning👇
ow.ly/3sWO50QQCSE

Endorsed by AASLD Foundation & Digestive Cancers Europe

#MedEd #HCC #IO

📢 Abstract submission system for ESMO - Eur. Oncology 2024 is now open!

⏲️ Submit by 7 May 2024

✅ Your research will gain immediate visibility and accepted abstracts will be published in ESMO’s flagship journal, Annals of Oncology.

Find out more👇
ow.ly/OTog50QQzp0

#MedEd #ESMO24

❗A 2023 meta-analysis by C. Fulgenzi et al. on the efficacy and safety of frontline systemic therapy for advanced #HCC .

✅ The study strongly consolidates the role of immunotherapy combinations as a mainstay of treatment.

Access here👇
ow.ly/Mo3X50QQ02Q

#LiverTwitter

Did you know that Hemostasis Connect is part of the wider COR2ED family?

You can find them all on X or here! ow.ly/wiu950Pwpcs

❗Some patients with advanced #HCC are not eligible for #IO because it would worsen their autoimmune conditions

What would be the preferred first-line treatment options?

💡Find out in the podcast developed by Prof. Saab and Prof. Harding👇
ow.ly/jqBw50QKsM7

#MedEd

❗ As we move on from the EASLnews #LiverCancerSummit 2024, here are some more abstracts we think may be of your interest

Search them up from the complete list👇
ow.ly/EB9n50QJ86b

✅ Follow us to stay up to date with the newest research regarding HCC

#MedEd #EASL24

❓Do you know the first line treatments for pts with advanced HCC?

Follow a patient's journey & make decisions about #HCC treatment in the interactive patient case video by Dr Vandamme👇
ow.ly/GL4k50QJ83S

Endorsed by Blue Faery Digestive Cancers Europe & Global Liver Institute

#MedEd

Now that the EASLnews 2024 is over, what was your favourite part?

We've made a list of some of the most exciting abstracts from the conference; search for them here👇
ow.ly/v1kc50QI7Mu

✅ Follow us to stay up to date with the newest research regarding #HCC

#MedEd